Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024
This report looks at a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) illness and hospitalization among Alaska Native children in …
Ask aRCie
Nirsevimab Frequently Asked Questions
This webpage provides answers to frequently asked questions (FAQs) about nirsevimab, a monoclonal antibody used to prevent RSV in infants and young children. Topics include …
What Is the New RSV Immunization for Infants?
This short video discusses a new FDA-approved product that prevents serious RSV disease in children. It's not a typical vaccine but a monoclonal antibody given …
Multiple Questions About Protection From Respiratory Syncytial Virus
2024
· University of Pennsylvania
This article, written by Stanley A. Plotkin, is about protecting people from respiratory syncytial virus (RSV). It describes key questions about protecting against respiratory syncytial …
Nirsevimab: Alleviating the Burden Of RSV Morbidity in Young Children
2024
· Duke-NUS Medical School,
· KK Women's & Children's Hospital,
· University of New South Wales,
· Macquarie University,
· National Centre for Immunisation Research and Surveillance (NCIRS)
This article reviews the real-world data that supports the effectiveness of nirsevimab, a monoclonal antibody that helps protect young children from RSV. Studies have demonstrated …
Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care
This article describes how a hospital successfully used nirsevimab to prevent RSV in newborns. They offered the immunization to 99% of eligible infants, with 71% …
Nirsevimab for Respiratory Syncytial Virus Prophylaxis in Newborns and Infants
2025
· Med Uni Graz
This editorial discusses the burden of respiratory syncytial virus (RSV) infection in young children, particularly infants under 6 months old or in their first RSV …
Nirsevimab and Abrysvo Update for the 2024-2025 Respiratory Season
2024
· Ohio Department of Health
This webpage provides an update on both infant nirsevimab (Beyfortus®) and maternal RSVpreF (Abrysvo™) administration and planning considerations. Infants can be protected against RSV through …
Immunization for Respiratory Syncytial Virus-Promises and Pitfalls
This editorial discusses the potential benefits and challenges of vaccines for the respiratory syncytial virus (RSV). It explains how RSV affects children and older adults, …
Pricey or Priceless: Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Prevention in Infants
2024
· University of Antwerp
This comment discusses the cost-effectiveness of preventing RSV in infants. It compares different strategies, like using monoclonal antibodies (nirsevimab) and a maternal vaccine (MV). It …